Corvus Pharmaceuticals, Inc.
NASDAQ:CRVSBiotechnology
-$0.19 today
- Market cap
- $857.87M
- Beta
- 0.84
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.49
Volume 0.93M
Average 1.49M
CRVS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Corvus Pharmaceuticals, Inc.NASDAQ: CRVS
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns negative
Q1 FY2026 EBITDA was -$11.88M, compared with $15.22M a year earlier. Trailing-twelve-month EBITDA was -$42.27M.
Context
- EBITDA grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +75.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$11.88M+3.4% QoQ
- Last fiscal yearDec 2025
- -$15.18M+75.6% YoY
- LTMMar 2026
- -$42.27M-2.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -178.1% | +100.0% | +278.1 pp |
| 1 year | +75.6% | +100.0% | +24.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (15.18M) USD
- Year-over-year change
- +75.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (15.18M) | +75.6% |
| FY2024 | 2024-12-31 | (62.21M) | -131.4% |
| FY2023 | 2023-12-31 | (26.88M) | +34.3% |
| FY2022 | 2022-12-31 | (40.94M) | +4.3% |
| FY2021 | 2021-12-31 | (42.77M) | — |
EBITDA vs competitors
How CRVS compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -2.3% is the 3rd highest of 9, against a peer median of -36.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.88M USD | +463.6% | — | 48.0% | |
| LTM Jun 2024 | -$36.06M USD | — | — | 4420.7% | |
| LTM Mar 2026 | -$42.27M USD | -2.3% | — | — | |
| FY2025 | -€43.65M EUR | +7.0% | — | 1566.1% | |
| LTM Mar 2026 | -$50.64M USD | -7.0% | — | 32.2% | |
| LTM Mar 2026 | -$57.67M USD | -232.5% | — | 162.2% | |
| LTM Mar 2026 | -$67.05M USD | -25.2% | — | — | |
| LTM Jun 2026 | -$134.39M USD | -53.9% | — | 246.2% | |
| LTM Mar 2026 | -$159.87M USD | -61.9% | — | 341.0% | |
| LTM Jun 2026 | -$419M USD | -48.6% | — | 358.1% | |
| Peer median (excluding CRVS) | — | -36.9% | — | 293.6% | |
Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 105K |
| Gross Profit | 0 | 0 | 0 | 0 | (105K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 29.12M | 24.47M | 16.53M | 19.39M | 33.72M |
| Selling, General & Admin | 9.52M | 8.1M | 6.88M | 8.16M | 9.25M |
| Operating Expenses | 38.63M | 32.57M | 23.41M | 27.55M | 42.87M |
| Depreciation & Amortization | 460K | 367K | 151K | 85K | 105K |
| EBITDA | (42.77M) | (40.94M) | (26.88M) | (62.21M) | (15.18M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (38.63M) | (32.57M) | (23.41M) | (27.55M) | (42.97M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 654K | 1.58M | 1.82M | 2.51M |
| Interest Expense | 15K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (4.61M) | (8.74M) | (3.62M) | (34.75M) | 27.69M |
| Income Before Tax | (43.24M) | (41.31M) | (27.03M) | (62.29M) | (15.28M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.24M) | (41.31M) | (27.03M) | (62.29M) | (15.28M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.03) | (0.89) | (0.56) | (1.02) | (0.19) |
| EPS (Diluted) | (1.03) | (0.89) | (0.56) | (1.02) | (0.53) |
| Weighted Avg Shares | 41.85M | 46.55M | 48.03M | 60.99M | 78.96M |
| Weighted Avg Shares (Diluted) | 41.85M | 46.55M | 48.03M | 60.99M | 79.74M |
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
Intrinsic Alpha fair value
Locked
Current Price
$10.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.